From Yahoo Finance: 2025-05-11 17:20:00

President Trump’s healthcare executive order aims to revamp Medicare drug price negotiations, a win for the sector. Drug makers seek to delay small-molecule drug price negotiations by four years. Trump’s order also targets slashing healthcare costs and follows a national security report on the pharma industry, potentially leading to sector-specific tariffs.

Ascentage Pharma Group Internat (NASDAQ:AAPG) is a clinical-stage biotech company with a YTD performance of 39.87%. The company recently released results from five preclinical studies on its drug candidates. Ascentage Pharma ranks 7th on the list of best performing healthcare stocks to buy now, with plans to advance its clinical development programs.

AAPG’s Chief Medical Officer highlighted the positive results of their drug investigations, anticipating advancements in clinical development. Two of the company’s drugs were included in the 2025 Chinese Society of Clinical Oncology Guidelines. While AAPG shows potential, there are AI stocks with higher return promises. One AI stock has gained since 2025, offering potential for massive gains.

AAPG continues to expand its treatment options through clinical development programs. With a Buy rating from J.P. Morgan, AAPG aims to strengthen its innovative pipeline. For investors seeking AI stocks with significant upside potential, exploring alternatives to AAPG with lower earnings ratios may offer promising opportunities.

Read more: Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now?